165 related articles for article (PubMed ID: 14752071)
81. Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care's gastrointestinal cancer disease site group.
Figueredo A; Charette ML; Maroun J; Brouwers MC; Zuraw L
J Clin Oncol; 2004 Aug; 22(16):3395-407. PubMed ID: 15199087
[TBL] [Abstract][Full Text] [Related]
82. Prognostic factors for disease-free survival in patients with T3-4 or N+ rectal cancer treated with preoperative chemoradiation therapy, surgery, and intraoperative irradiation.
Díaz-González JA; Calvo FA; Cortés J; García-Sabrido JL; Gómez-Espí M; Del Valle E; Muñoz-Jiménez F; Alvarez E
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1122-8. PubMed ID: 16406393
[TBL] [Abstract][Full Text] [Related]
83. Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.
Petrelli F; Labianca R; Zaniboni A; Lonardi S; Galli F; Rulli E; Rosati G; Corallo S; Ronzoni M; Cardellino GG; Mattioli R; Mambrini A; Ciuffreda L; Banzi M; Pusceddu V; Maiello E; Zampino M; Zagonel V; Marchetti P; Corsi D; Rimassa L; Cinieri S; Sobrero A
JAMA Oncol; 2020 Apr; 6(4):547-551. PubMed ID: 32053133
[TBL] [Abstract][Full Text] [Related]
84. Adjuvant therapy with protein-bound polysaccharide K and tegafur uracil in patients with stage II or III colorectal cancer: randomized, controlled trial.
Ohwada S; Kawate S; Ikeya T; Yokomori T; Kusaba T; Roppongi T; Takahashi T; Nakamura S; Kawashima Y; Nakajima T; Morishita Y;
Dis Colon Rectum; 2003 Aug; 46(8):1060-8. PubMed ID: 12907900
[TBL] [Abstract][Full Text] [Related]
85. Mitomycin C plus carmofur (HCFU) adjuvant chemotherapy for noncuratively resected cases of colorectal carcinoma (interim report).
Niimoto M; Hattori T; Tamada R; Sugimachi K; Inokuchi K; Ogawa N
Jpn J Surg; 1987 Sep; 17(5):354-61. PubMed ID: 3123756
[TBL] [Abstract][Full Text] [Related]
86. [Analysis of microsatellite instability and p53 LOH in advanced colorectal cancers--first report of the No. 3 protocol].
Tomita N; Monden M; Kikkawa N; Imamura M; Ohtoshi M; Ohhashi S; Sakamoto T; Tanigawa N; Nakano H; Hioki K; Hirakawa K; Yasutomi M; Yamamura T; Kameyama M; Iwanaga T;
Gan To Kagaku Ryoho; 2004 Mar; 31(3):367-72. PubMed ID: 15045942
[TBL] [Abstract][Full Text] [Related]
87. [Prospective adjuvant chemotherapy, with mitomycin C plus long-term carmofur in colorectal cancer].
Terabe K; Yamauchi M; Watanabe T; Ichihashi H; Takagi H; Imaizumi M; Kondo T
Gan No Rinsho; 1986 Mar; 32(3):261-7. PubMed ID: 3086597
[TBL] [Abstract][Full Text] [Related]
88. [Neo-adjuvant chemotherapy with carmofur for colorectal cancer--a multi-institutional randomized controlled study].
Kotake K; Koyama Y; Shida S; Tajima Y; Ishikawa H; Kanazawa K; Miyata M; Nagamachi Y; Iwasaki Y; Omoto R; Tamakuma S; Kitajima M; Kodaira S;
Gan To Kagaku Ryoho; 2002 Nov; 29(11):1917-24. PubMed ID: 12465390
[TBL] [Abstract][Full Text] [Related]
89. The use of adjuvant chemotherapy is not associated with recurrence or cancer-specific death following curative resection for stage III rectal cancer: a competing risks analysis.
Ng KS; Chan C; Rickard MJFX; Keshava A; Stewart P; Chapuis PH
World J Surg Oncol; 2023 May; 21(1):152. PubMed ID: 37198644
[TBL] [Abstract][Full Text] [Related]
90. Cumulative incidence of first recurrence after curative treatment of stage I-III colorectal cancer. Competing risk analyses of temporal and anatomic patterns.
Storli PE; Dille-Amdam RG; Skjærseth GH; Gran MV; Myklebust TÅ; Grønbech JE; Bringeland EA
Acta Oncol; 2023 Dec; 62(12):1822-1830. PubMed ID: 37862319
[TBL] [Abstract][Full Text] [Related]
91. The role of meta-analysis in cancer clinical trials.
Hamada C
Int J Clin Oncol; 2009 Apr; 14(2):90-4. PubMed ID: 19390938
[TBL] [Abstract][Full Text] [Related]
92. Clinical management of localized colon cancer with capecitabine.
Quidde J; Arnold D; Stein A
Clin Med Insights Oncol; 2012; 6():363-73. PubMed ID: 23170068
[TBL] [Abstract][Full Text] [Related]
93. Prevention of Colon Cancer Recurrence From Minimal Residual Disease: Computer Optimized Dose Schedules of Intermittent Apoptotic Adjuvant Therapy.
Cockrell C; Teague J; Axelrod DE
JCO Clin Cancer Inform; 2020 Jun; 4():514-520. PubMed ID: 32510974
[TBL] [Abstract][Full Text] [Related]
94. Exploring and validating surrogate endpoints in colorectal cancer.
Burzykowski T; Buyse M; Yothers G; Sakamoto J; Sargent D
Lifetime Data Anal; 2008 Mar; 14(1):54-64. PubMed ID: 18205045
[TBL] [Abstract][Full Text] [Related]
95. Comparison of the antifungal activity of the pyrimidine analogs flucytosine and carmofur against human-pathogenic dematiaceous fungi.
Coelho RA; Almeida-Silva F; Figueiredo-Carvalho MHG; Rabello VBS; de Souza GR; Lourenço MCDS; Rodrigues ML; Almeida-Paes R
Med Mycol; 2024 Mar; 62(4):. PubMed ID: 38533658
[TBL] [Abstract][Full Text] [Related]
96. Recurrence-free survival dynamics following adjuvant chemotherapy for resected colorectal cancer: A systematic review of randomized controlled trials.
Vail E; Choubey AP; Alexander HR; August DA; Berry A; Boland PM; Eskander MF; Grandhi MS; Haliani B; In H; Kennedy TJ; Langan RC; Maggi JC; Pitt HA; Ganesan S; Ecker BL
Cancer Med; 2024 Jan; 13(1):. PubMed ID: 38186327
[TBL] [Abstract][Full Text] [Related]
97. Apurinic/apyrimidinic endonuclease 1 is associated with poor prognosis after curative resection followed by adjuvant chemotherapy in patients with stage III colon cancer.
Song JH; Lee MS; Cha EY; Lee KH; Kim JY; Kim JS
Korean J Clin Oncol; 2022 Jun; 18(1):1-10. PubMed ID: 36945334
[TBL] [Abstract][Full Text] [Related]
98. Outcomes of Adjuvant Oral versus Intravenous Fluoropyrimidines for High-Risk Stage II or Stage III Colon Adenocarcinoma: A Propensity Score-Matched, Nationwide, Population-Based Cohort Study.
Zhang J; Yen YC; Qin L; Chang CL; Yuan KS; Wu ATH; Wu SY
J Cancer; 2020; 11(14):4157-4165. PubMed ID: 32368298
[No Abstract] [Full Text] [Related]
99. Essential advances in surgical and adjuvant therapies for colorectal cancer 2018-2019.
Akagi T; Inomata M
Ann Gastroenterol Surg; 2020 Jan; 4(1):39-46. PubMed ID: 32021957
[TBL] [Abstract][Full Text] [Related]
100. Predictive Impact of Mucinous Tumors on the Clinical Outcome in Patients with Poorly Differentiated, Stage II Colon Cancer: A TOSCA Subgroup Analysis.
Rosati G; Galli F; Cantore M; Bergamo F; Banzi M; Zampino MG; Mattioli R; Cardellino GG; Ronzoni M; Di Bartolomeo M; Tamberi S; Marchetti P; Rimassa L; Corsi D; Bochicchio AM; Artioli F; Labianca R; Galli F; Rulli E; Bilancia D; Bregni G;
Oncologist; 2020 Jun; 25(6):e928-e935. PubMed ID: 31943506
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
